Published in Gene Therapy Weekly, October 20th, 1997
Under the agreement, CRCT has licensed Agouron patented prototype inhibitors of the enzyme poly ADP-ribose polymerase (PARP) discovered by the Anti-cancer Drug Discovery Initiative (ADDI) at Newcastle. PARP has been shown to play a key role in the ability of certain human cancers to evade currently available anti-tumor drugs.
Agouron will support...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.